研究

姚小軍 Yao Xiaojun

---

 個人簡介

姚小軍博士，現任職澳門理工大學應用科學學院教授。在Nature.Mach. Intell., Pharmacol Ther., Brief. Bioinf, Cancer Lett., Antioxid Redox Signal., Cell Death Dis., Pharmacol Res.,  Chem. Eng. J.等刊物上作為第一作者或通訊作者發表學術論文160餘篇。發表的論文被引用被引用16,000餘次。主持和完成國家自然科學基金，澳門科學技術發展基金及橫向課題20餘項。

 學習工作經歷

學習經歷：
2002.1-2004.12 巴黎第七大學 化學信息與理論化學 博士
1998.9-2003.7   蘭州大學化學化工學院 分析化學 博士
1994.9-1998.7   蘭州大學化學系 高分子化學 學士

工作經歷：
2023.7--至今     澳門理工大學，應用科學學院，教授
2013.7-2023.6  澳門科技大學，中藥質量研究國家重點實驗室，教授
2005.1-2013.6  蘭州大學，化學化工學院，教授

 研究領域

• 人工智能藥物發現
• 藥物和靶標相互作用的多尺度分子模擬
• 分子靶向抗腫瘤候選藥物的發現及作用機理研究

 研究成果（近三年代表性論文）

1. Y, Li; C, Hsieh; R, Lu; X, Gong; X, Wang; P, li; S, Liu; Y, Tian; D, Jiang; J, Yan; Q, Bai; H, Liu; S, Zhang; X, Yao^*, An adaptive graph learning method for automated molecular interactions and properties predictions, Nat Mach Intell. 2022, 4: 645-651.
2. J, Zhang; P, Liu; J, Chen; D, Yao; Q, Liu; J, Zhang; H, Zhang; E, Leung^*; X, Yao^*; L, Liu^*, Upgrade of chrysomycin A as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression, Pharmacol Res. 2022, 187:106565.
3. J, Zhang; J, Zhang; Q, Liu; X, Fan; E, Leung^*; X, Yao^*; L, Liu^*, Resistance looms for KRAS G12C inhibitors and rational tackling strategies, Pharmacol Ther. 2022, 229:108050
4. X, Wang; Z, Jiang; C, Xu; W, Meng; P, Liu; Y, Zhang; C, Xie; J, Xu; Y, Xie; T, Liang; H, Yan; X, Fan; X, Yao^*; Q, Wu^*; E, Leung^*, Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response, Pharmacol Res. 2022, 179:106198
5. E, Leung^*; J, Huang; J, Zhang; J, Zhang; M, Wang; Y, Zhu; Z, Meng; H, Yu; E, Neher; L, Ma^*; X, Yao^*, Novel Anticancer Strategy by Targeting the Gut Microbial Neurotransmitter Signaling to Overcome Immunotherapy Resistance, Antioxid Redox Signal. 2022,38:298-315 
6. Zhang, Q.; Zhao, N.; Meng, X.; Yu, F.; Yao, X.; Liu, H.* The prediction of protein–ligand unbinding for modern drug discovery. Expert. Opin. Drug Discov. 2022, 17, 191-205.
7. X, Wang; Y, Li; J, Qiu; G, Chen; H, Liu; B, Liao^*; C, Hsieh^*; X, Yao^*, RetroPrime: A Diverse, plausible and Transformer-based method for Single-Step retrosynthesis predictions, Chem Eng J. 2021, 420:129845
8. Y, Li; P, Li; X, Yang; C, Hsieh; S, Zhang; X, Wang; R, Lu; H, Liu; X, Yao^*, Introducing block design in graph neural networks for molecular properties prediction, Chem Eng J. 2021, 414:128817
9. P, Li; Y, Li; C, Hsieh; S, Zhang; X, Liu; H, Liu; S, Song^*; X, Yao^*, TrimNet: learning molecular representation from triplet messages for biomedicine, Brief Bioinform. 2021, 22:bbaa266
10. Q, Wang; X, Shao; E, Leung; Y, Chen^*; X, Yao^*, Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms, Pharmacol Res. 2021, 172:105804
11. Z, Jiang; W, Wang; C, Xu; Y, Xie; X, Wang; Y, Zhang; J, Huang; M, Huang; C, Xie; P, Liu; X, Fan; Y, Ma; P, Yan; L, Liu; X, Yao^*; Q, Wu^*; E, Leung^*, Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer, Cancer Lett. 2021, 515: 36-48.
12. H, Lai; X, Fan; R, Li; Y, Wang; J, Zhang; L, Liu; E, Neher; X, Yao^*; E, Leung^*, Roles of Ion Fluxes, Metabolism, and Redox Balance in Cancer Therapy, Antioxid Redox Sign. 2021, 34: 1108-1127.
13. F, Wang; W, Ye; S, Wang; Y, He; H, Zhong; Y, Wang; Y, Zhu; J, Han; Z, Bing; S, Ji; H, Liu^*; X, Yao^*, Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy, Neoplasia. 2021, 23: 281-293.
14. J, Han; Y, Zhu; D, Pan; H, Xue; S, Wang; Y, Peng; H, Liu^*; Y, He^*; X, Yao^*, Discovery of pentapeptide-inhibitor hits targeting FKBP51 by combining computational modeling and X-ray crystallography, Comput Struct Biotechnol J. 2021, 19: 4079-4091.
15. W, Wang; L, Mao; H, Lai; Y, Wang; Z, Jiang; W, Li; J, Huang; Y, Xie; C, Xu; P, Liu; Y, Li^*; E, Leung^*; X, Yao^*, Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway, Pharmacol Res. 2020, 161: 105129